Tizona Therapeutics, Inc   Report issue

For profit Phase 1
Founded: South San Francisco CA United States (2014)
Status: Acquired by Gilead Sciences (2020)

Organization Overview

First Clinical Trial
2019
NCT03884556
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Tizona Therapeutics, Inc

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lymphoma (Phase 1)

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 3
  • # of Trial APIs: 10